Regenerex Pharma (RGPX) EBT (2010 - 2025)

Regenerex Pharma (RGPX) has 13 years of EBT data on file, last reported at -$790709.0 in Q3 2025.

• EBT for Q3 2025 came in at -$790709.0, down 50.74% year-over-year; the trailing twelve-month figure through Sep 2025 was -$3.1 million (down 117.87% YoY), and the FY2025 annual result was -$2.1 million, up 39.48% from the prior year.
• EBT declined to -$790709.0 in Q3 2025 per RGPX's latest filing, from -$657379.0 in the prior quarter.
• Over five years, EBT peaked at -$24430.0 in Q2 2021 and troughed at -$2.8 million in Q3 2023.
• A 5-year average of -$438483.0 and a median of -$219141.5 in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2024: EBT tumbled 7261.98% in 2023, then surged 81.3% in 2024.
• A 5-year view of EBT shows it stood at -$76523.0 in 2021, then jumped by 39.44% to -$46343.0 in 2022, then plunged by 460.18% to -$259603.0 in 2023, then plunged by 30.4% to -$338526.0 in 2024, then plunged by 133.57% to -$790709.0 in 2025.
• Business Quant data shows RGPX's EBT at -$790709.0 in Q3 2025, -$657379.0 in Q2 2025, and -$1.3 million in Q1 2025.